Table 3. Baseline adiponectin level (continuous variable, log transformed) and outcomes.
| RRT | Composite renal outcome | All-cause mortality | ||||
|---|---|---|---|---|---|---|
| HR (95%CI)* | P | HR (95%CI)* | P | HR (95%CI)* | P | |
| Unadjusted | 1.98 (1.17–3.39) | 0.01 | 1.77 (1.19–2.63) |
0.005 | 1.98 (1.05–3.72) |
0.04 |
| Adjusted | ||||||
| Model 1b | 1.94 (1.10–3.43) | 0.02 | 1.69 (1.11–2.59) |
0.02 | 1.10 (0.53–2.27) |
0.80 |
| Model 2c | 2.08 (1.17–3.72) | 0.01 | 1.78 (1.15–2.75) |
0.01 | 1.04 (0.49–2.22) |
0.91 |
| Model 3d | 2.08 (1.08–4.02) | 0.03 | 1.66 (1.03–2.65) | 0.04 | 0.93 (0.41–2.10) | 0.86 |
*Per unit increase in log-transformed adiponectin
b Adjusted for age, gender, BMI, gout
c Adjusted for model 1 covariates plus metabolic syndrome criteria: (1) central obesity (waist circumference ≥ 90 cm in men or ≥ 80 cm in women, according to the ethnic criteria for Asians); (2)TG ≥ 150 mg/dL; (3) HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women; (4) fasting glucose ≥ 100 mg/dL or previously diagnosed with type 2 DM; (5) BP ≥ 130/85 mmHg or on treatment for hypertension
d Adjusted for model 2 covariates plus Hb, Albumin, CRP, eGFR, UPCR
Values expressed as hazard ratios (HR) and 95% confidence interval (CI).